you are here:

Fresenius Kabi Oncology Ltd.

BSE: 532545 | NSE: FKONCO | Series: NA | ISIN: INE575G01010 | SECTOR: Pharmaceuticals

BSE Live

Jan 02, 15:50
132.45 0.00 (0.00%)
Volume
No Data Available
91,518
  • Prev. Close

    132.45

  • Open Price

    132.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    132.45 (20430)

Fresenius Kabi Oncology is not traded on BSE in the last 30 days

NSE Live

Nov 17, 15:16
1348.00 0.00 (0.00%)
Volume
No Data Available
1,345
  • Prev. Close

    1348.00

  • Open Price

    1343.88

  • Bid Price (Qty.)

    1348.00 (4)

  • Offer Price (Qty.)

    1351.46 (1)

Fresenius Kabi Oncology is not traded on NSE in the last 30 days
Company History - Fresenius Kabi Oncology
2003
 
 -Sets up a new six member board to give strategic inputs and
 direction to the company
 
 2004
 
 -Dabur Pharma enters NSE, BSE
 
 2006
 
 -Dabur Pharma Limited has informed that Mr. V. V. Dharkar has joined
 the Company as Chief Financial Officer w.e.f December 01, 2006.
 
 2007
 
 -Dabur Pharma on January 4,2007 unveiled new nano technology based
 chemotherapy agent, Nanoxel, in the country.
 
 -Dabur Pharma has informed that Mr. Shailendra Tandon has joined the
 Company as Chief Financial Officer w.e.f. June 26, 2007.
 
 2009
 
 - Company name has been changed from Dabur Pharma Ltd to Fresenius
 Kabi Oncology Ltd.
 
 
 2010
 
 - Opening of newly developed premier Innovation & Development Center
 and Corporate Office at Gurgaon.
 
 - Fresenius Kabi Oncology Ltd Enters Into a Licensing And Settlement
 Agreement with Sanofi-Aventis.
 
 2011
 
 - Dissolution of Wholly owned Subsidiary Dabur Pharma (Thailand) Co.
 Ltd.